It's time to start talking about $WINT (Windtree Therapeutics)

Long time watcher, first time poster... I'm very surprised at the lack of mentions here about WINT, and am honestly wondering why so many are overlooking this potential golden ticket, especially at a time when smaller, heavily shorted bio floats (especially ones with a Covid link) are taking off with the slightest piece of news. Here's the quick DD breakdown: Five trials in Phase 2. Check out the full pipeline here. Several trial updates are due over the next few months, including one that's imminent and related to Covid lung injury. This is actually bigger news than most realize too. Search KL4 and you will realize that the product has already been FDA approved for other uses (early 2010s), so there's potential for fast track here with the Delta variant taking hold. Recent $8 price target from Oppenheimer. 7.8M public float. 20% of float is shorted. 150K share buy from the lead director in March @ $2.36. Recent offering @ $3.25 in March, leaving a cash runway that should last until at least mid-next year. One final interesting nugget worth noting here, there's speculation that they will either merge or be bought out by a larger company before end of year. This speculation comes from something that was said during the recent Ladenburg Thalmann Healthcare Conference - Craig Fraser alluded to something "transactional" happening by the end of this year (7:07 mark here). WINT closed at $1.83 on Friday, that's well over 400% off its one-year high of $10.06. It's badly beaten down, heavily shorted, and primed to run hard once they start releasing news. My price target is $10 by end of year, and $6-7 by end of August (KL4 release). A lot of people either don't know about this stock or are downplaying the importance of their Istaroxime candidate. Their buyout price would be higher than $10 based on their assets and pipeline alone IMO. As always, do your own DD. This is not financial advice. Position: 15K shares @ $1.87 and continuing to add as much as I can below $2.

back
scot-tagscot-icon

Scouted Idea

We scour the net for great ideas, so you don't have to

Original Post

portfolio-reddit logo

UghImNewHere

Jul 26, 2021

-1.09%

Change % Since Posting

1.84

Price When Posted

-0.02

Change Since Posting

WINT

Windtree Therapeutics Inc

1.82

0.00
0.00%
Current Price

Is this your Reddit account?

Claim this username to collect earnings from this post, and the portfolio!

portfolio reddit logoportfolio utradea logo

It's time to start talking about $WINT (Windtree Therapeutics)

bullish

Long time watcher, first time poster...

I'm very surprised at the lack of mentions here about WINT, and am honestly wondering why so many are overlooking this potential golden ticket, especially at a time when smaller, heavily shorted bio floats (especially ones with a Covid link) are taking off with the slightest piece of news.

Here's the quick DD breakdown:

  • Five trials in Phase 2. Check out the full pipeline here.
  • Several trial updates are due over the next few months, including one that's imminent and related to Covid lung injury. This is actually bigger news than most realize too. Search KL4 and you will realize that the product has already been FDA approved for other uses (early 2010s), so there's potential for fast track here with the Delta variant taking hold.
  • Recent $8 price target from Oppenheimer.
  • 7.8M public float.
  • 20% of float is shorted.
  • 150K share buy from the lead director in March @ $2.36.
  • Recent offering @ $3.25 in March, leaving a cash runway that should last until at least mid-next year.

One final interesting nugget worth noting here, there's speculation that they will either merge or be bought out by a larger company before end of year. This speculation comes from something that was said during the recent Ladenburg Thalmann Healthcare Conference - Craig Fraser alluded to something "transactional" happening by the end of this year (7:07 mark here).

WINT closed at $1.83 on Friday, that's well over 400% off its one-year high of $10.06. It's badly beaten down, heavily shorted, and primed to run hard once they start releasing news. My price target is $10 by end of year, and $6-7 by end of August (KL4 release). A lot of people either don't know about this stock or are downplaying the importance of their Istaroxime candidate. Their buyout price would be higher than $10 based on their assets and pipeline alone IMO.

As always, do your own DD. This is not financial advice.

Position: 15K shares @ $1.87 and continuing to add as much as I can below $2.

Comments

Write your comment....

Sign in to comment

read-time
1 min

7.00

Target Price

9/ 10

Confidence

1-2 Months

Timeframe
catalyst icon
Earnings Release
catalyst icon
News
catalyst icon
SEC Filing
catalyst icon
Sentiment
catalyst icon
Other Catalyst

WINT Channel

Start new chat
next